ccNexfin Monitors BP, CO, Hemoglobin, SpO2

BMEYE out of Amsterdam, the Netherlands won FDA approval to bring to U.S. market its ccNexfin cardiovascular patient monitor. The device features noninvasive cardiovascular monitoring of blood pressure, cardiac output, and includes Masimo‘s rainbow SET Pulse CO-Oximetry for continuous hemoglobin and oxygen saturation monitoring.

Hemodynamic monitoring has traditionally relied upon invasive, costly, intermittent, or unreliable methods to assist clinicians in maintaining adequate oxygen delivery and tissue perfusion to prevent hypoxia and its irreversible damage. However, the ccNexfin with Masimo rainbow SET offers a totally noninvasive method of providing some of the most advanced cardiovascular and hemodynamic monitoring capabilities available today. It utilizes a BMEYE finger cuff to capture and continuously measure beat-to-beat blood pressure (sys/dia), mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR), and derivative of pressure (dP/dt), and a Masimo finger sensor to noninvasively and continuously measure hemoglobin (SpHb(R)), oxygen saturation (SpO2), oxygen content (SpOC(TM)), and perfusion index (PI).

Press release: BMEYE Receives FDA Clearance to Launch ccNexfin, the First Totally Noninvasive Cardiovascular Monitor With BP, CO, and Masimo Rainbow SET(R) Technology in the United States…
Product page: ccNexfin …